Systemic sclerosis & Raynaud's
Nailfold capillaroscopy in patients with systemic sclerosis-associated interstitial lung disease: a substudy of the SENSCIS trial
Authors' conclusion
In a substudy of the SENSCIS trial, numerical differences in changes in capillary density assessed by NC over 52 weeks may suggest a potential effect of nintedanib in patients at risk of ILD progression.
Study context
- Population
- Patients with SSc-ILD in the SENSCIS trial
- Comparison
- Nintedanib vs placebo
- Primary endpoint
- Microvascular changes in nailfold capillaries on NC (capillary density, giant capillaries, abnormal shapes, % fingers with microhaemorrhages)
- Follow-up
- Week 52
Methodological detailssubstudy
- Substudy
Primary result
As reported in the abstract
NC measurements, overall groups
- No notable changes in any nailfold capillaroscopy (NC) measurement in the overall placebo or nintedanib groups
Further findings
Mean capillary density in patients with risk factors for rapid forced vital capacity (FVC) decline (subgroup) · 52 weeks
- Numerical reduction with placebo; stable with nintedanib (n=38)
Mean capillary density in patients with ILD progression (subgroup) · 52 weeks
- Numerical increase with nintedanib; stable with placebo (n=11)
Capillary density in patients without risk factors for rapid FVC decline or without ILD progression (subgroups) · week 52
- No notable changes
Original publication
Nailfold capillaroscopy in patients with systemic sclerosis-associated interstitial lung disease: a substudy of the SENSCIS trial. RMD Open. Published 17 October 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →